Risankizumab, an IL-23p19 Inhibitor for Psoriasis

A Review of the Current Literature

Julian McDonald, BSc(Hons); Khalad Maliyar, BA; Melinda J. Gooderham, MD, MSc, FRCPC


Skin Therapy Letter. 2020;25(3):1-4. 

In This Article

Abstract and Introduction


Psoriasis is a common, chronic, immune-mediated, inflammatory disorder with significant skin manifestations and substantial burden on quality of life. Interleukin-23 is a key regulator of different effector cytokines and plays a cardinal role in the pathogenesis of psoriasis. The monoclonal antibody, risankizumab, inhibits this key cytokine and thus prevents the downstream inflammatory cascade. This article aims to review our current understanding of risankizumab through the analysis of the various clinical trials.